资料显示，安徽华人健康医药股份有限公司位于安徽省合肥市河北路123号A1栋，成立日期2001年6月 29日，上市日期2023年3月1日，公司主营业务涉及主要从事医药代理、零售及终端集采三大块业务。主 营业务收入构成为：中西成药97.60%，其他(补充)2.40%。 截至9月30日，华人健康股东户数2.01万，较上期减少22.86%；人均流通股7422股，较上期增加 29.64%。2025年1月-9月，华人健康实现营业收入38.92亿元，同比增长19.06%；归母净利润1.57亿元， 同比增长45.21%。 分红方面，华人健康A股上市后累计派现8000.20万元。 来源：新浪证券-红岸工作室 1月6日，华人健康跌1.29%，成交额6.41亿元。两融数据显示，当日华人健康获融资买入额7720.13万 元，融资偿还6440.60万元，融资净买入1279.53万元。截至1月6日，华人健康融资融券余额合计1.99亿 元。 融资方面，华人健康当日融资买入7720.13万元。当前融资余额1.99亿元，占流通市值的6.97%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，华人健康1月6日融券偿还0.00股，融券卖 ...

Group 1 - The core viewpoint of the news is that Huaren Health's stock performance and financial metrics indicate a mixed outlook, with significant financing activity and growth in revenue and profit [1][2]. - On September 2, Huaren Health's stock fell by 1.07%, with a trading volume of 97.69 million yuan, and a net financing purchase of 3.92 million yuan [1]. - As of September 2, the total margin balance for Huaren Health was 148 million yuan, accounting for 7.17% of its market capitalization, indicating a high level of financing compared to the past year [1]. Group 2 - For the first half of 2025, Huaren Health reported a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%, and a net profit attributable to shareholders of 104 million yuan, up 42.17% year-on-year [2]. - The number of shareholders increased to 26,100 as of June 30, 2025, a rise of 45.15%, while the average circulating shares per person decreased by 31.10% to 5,725 shares [2]. - Since its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3].

Group 1 - The core viewpoint of the news is that Huaren Health experienced a decline in stock price and trading volume, with significant financing activities indicating high investor interest despite the drop [1] - On August 14, Huaren Health's stock fell by 3.97%, with a trading volume of 232 million yuan, and a net financing purchase of 8.51 million yuan [1] - As of August 14, the total financing and securities lending balance for Huaren Health was 173 million yuan, representing 8.00% of its market capitalization, which is above the 90th percentile of the past year [1] Group 2 - Huaren Health's main business segments include pharmaceutical agency, retail, and terminal procurement, with the revenue composition being 80.25% from Western and Chinese medicines, 4.62% from health products, and 4.00% from medical devices [1] - As of March 31, the number of shareholders for Huaren Health increased by 9.39% to 18,000, while the average circulating shares per person decreased by 8.58% to 8,309 shares [2] - For the first quarter of 2025, Huaren Health reported a revenue of 1.267 billion yuan, a year-on-year increase of 14.71%, and a net profit attributable to shareholders of 61.22 million yuan, up 28.15% year-on-year [2] Group 3 - Since its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3] - As of March 31, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders of Huaren Health [3]